SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 May 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Adverse reactions
Acronyms SAFE-HEaRt

16 Jun 2020 Status changed from active, no longer recruiting to completed.
31 May 2020 Results evaluating Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
19 Dec 2018 Planned End Date changed from 1 Aug 2018 to 1 Mar 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com